Headlines about Oncobiologics (NASDAQ:ONS) have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern rates the sentiment of media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Oncobiologics earned a news impact score of 0.13 on Accern’s scale. Accern also gave news coverage about the company an impact score of 41.6406735862342 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Shares of Oncobiologics (ONS) traded down $0.02 during trading hours on Friday, hitting $1.15. The stock had a trading volume of 6,991 shares, compared to its average volume of 40,569. Oncobiologics has a 12 month low of $0.78 and a 12 month high of $3.95. The company has a debt-to-equity ratio of -0.40, a quick ratio of 0.14 and a current ratio of 0.14.
In other news, CFO Lawrence A. Kenyon sold 26,165 shares of the firm’s stock in a transaction dated Friday, December 22nd. The stock was sold at an average price of $1.13, for a total value of $29,566.45. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Pankaj Mohan sold 114,677 shares of the firm’s stock in a transaction dated Thursday, January 4th. The shares were sold at an average price of $1.17, for a total value of $134,172.09. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 284,508 shares of company stock worth $328,317. 33.50% of the stock is currently owned by company insiders.
WARNING: This news story was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/01/19/oncobiologics-ons-receiving-somewhat-positive-media-coverage-accern-reports.html.
Oncobiologics Company Profile
Oncobiologics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, manufacturing and commercializing biosimilar therapeutics. It is focused on monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. The Company offers BioSymphony Platform.
Receive News & Ratings for Oncobiologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncobiologics and related companies with MarketBeat.com's FREE daily email newsletter.